GPT and metabolic dysfunction-associated steatotic liver disease: In a larger cohort of patients with NAFLD, although still without control group, saroglitazar also improved LFT, including ALT (56.47 ± 15.17 vs. 42.3 ± 11.26 IU/l; p < 0.0001), AST (48.57 ± 13.15 vs. 36.63 ± 8.14 IU/l; p < 0.0001), and GGT (54.97 ± 9.52 vs. 45.33 ± 5.94 IU/l; p < 0.0001) [123].